Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Agomab announced that the first patient has been dosed in NOV-ERA, the Company's Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD.